[ad_1]
Siegel RL, Miller KD, Fuchs HE, Jemal A. Most cancers Statistics, 2021. CA Most cancers J Clin. 2021;71:7–33. https://doi.org/10.3322/caac.21654.
Moch H, Cubilla AL, Humphrey PA, Reuter VE, Ulbright TM. The 2016 WHO classification of tumours of the urinary system and male genital organs-part A: renal, penile, and testicular tumours. Eur Urol. 2016;70:93–105. https://doi.org/10.1016/j.eururo.2016.02.029.
Werntz RP, Adamic B, Steinberg GD. Rising therapies within the administration of high-risk non-muscle invasive bladder most cancers (HRNMIBC). World J Urol. 2019;37:2031–40. https://doi.org/10.1007/s00345-018-2592-0.
Royce TJ, Feldman AS, Mossanen M, Yang JC, Shipley WU, Pandharipande PV, et al. Comparative Effectiveness of bladder-preserving tri-modality remedy versus radical cystectomy for muscle-invasive bladder most cancers. Clin Genitourin Most cancers. 2019;17:23-31.e3. https://doi.org/10.1016/j.clgc.2018.09.023.
Sanli O, Dobruch J, Knowles MA, Burger M, Alemozaffar M, Nielsen ME, et al. Bladder most cancers. Nat Rev Dis Primers. 2017;3:17022. https://doi.org/10.1038/nrdp.2017.22.
FDA approves first focused remedy for metastatic bladder most cancers | FDA [Internet]. [cited 13 Oct 2021]. https://www.fda.gov/news-events/press-announcements/fda-approves-first-targeted-therapy-metastatic-bladder-cancer
Grivas P, Monk BJ, Petrylak D, Reck M, Foley G, Guenther S, et al. Immune checkpoint inhibitors as change or continuation upkeep remedy in strong tumors: rationale and present state. Goal Oncol. 2019;14:505–25. https://doi.org/10.1007/s11523-019-00665-1.
Rotte A, Jin JY, Lemaire V. Mechanistic overview of immune checkpoints to help the rational design of their mixtures in most cancers immunotherapy. Ann Oncol. 2018;29:71–83. https://doi.org/10.1093/annonc/mdx686.
Gopalakrishna A, Longo TA, Fantony JJ, Owusu R, Foo W-C, Sprint R, et al. The diagnostic accuracy of urine-based checks for bladder most cancers varies vastly by affected person. BMC Urol. 2016;16:30. https://doi.org/10.1186/s12894-016-0147-5.
Yafi FA, Brimo F, Steinberg J, Aprikian AG, Tanguay S, Kassouf W. Potential evaluation of sensitivity and specificity of urinary cytology and different urinary biomarkers for bladder most cancers. Urol Oncol. 2015;33(66):e25-31. https://doi.org/10.1016/j.urolonc.2014.06.008.
Gandhi N, Krishna S, Sales space CM, Breau RH, Flood TA, Morgan SC, et al. Diagnostic accuracy of magnetic resonance imaging for tumour staging of bladder most cancers: systematic assessment and meta-analysis. BJU Int. 2018;122:744–53. https://doi.org/10.1111/bju.14366.
Lamm DL, Allaway M. Present tendencies in bladder most cancers remedy. Ann Chir Gynaecol. 2000;89:234–41.
Hussain MHA, Wooden DP, Bajorin DF, Bochner BH, Dreicer R, Lamm DL, et al. Bladder most cancers: narrowing the hole between proof and apply. J Clin Oncol. 2009;27:5680–4. https://doi.org/10.1200/JCO.2009.23.6901.
Track W, Anselmo AC, Huang L. Nanotechnology intervention of the microbiome for most cancers remedy. Nat Nanotechnol. 2019;14:1093–103. https://doi.org/10.1038/s41565-019-0589-5.
Sensible JD. The fundamentals and underlying mechanisms of mucoadhesion. Adv Drug Deliv Rev. 2005;57:1556–68. https://doi.org/10.1016/j.addr.2005.07.001.
Şenyiğit ZA, Karavana SY, İlem-Özdemir D, Çalışkan Ç, Waldner C, Şen S, et al. Design and analysis of an intravesical supply system for superficial bladder most cancers: preparation of gemcitabine HCl-loaded chitosan-thioglycolic acid nanoparticles and comparability of chitosan/poloxamer gels as carriers. Int J Nanomedicine. 2015;10:6493–507. https://doi.org/10.2147/IJN.S93750.
He M-H, Chen L, Zheng T, Tu Y, He Q, Fu H-L, et al. Potential purposes of nanotechnology in urological most cancers. Entrance Pharmacol. 2018;9:745. https://doi.org/10.3389/fphar.2018.00745.
Barani M, Hosseinikhah SM, Rahdar A, Farhoudi L, Arshad R, Cucchiarini M, et al. Nanotechnology in bladder most cancers: analysis and remedy. Cancers (Basel). 2021. https://doi.org/10.3390/cancers13092214.
Jain P, Kathuria H, Momin M. Scientific therapies and nano drug supply programs for urinary bladder most cancers. Pharmacol Ther. 2021;226: 107871. https://doi.org/10.1016/j.pharmthera.2021.107871.
Babjuk M, Burger M, Compérat EM, Gontero P, Mostafid AH, Palou J, et al. European affiliation of urology tips on non-muscle-invasive bladder most cancers (TaT1 and carcinoma in situ)—2019 replace. Eur Urol. 2019;76:639–57. https://doi.org/10.1016/j.eururo.2019.08.016.
Nossier AI, Eissa S, Ismail MF, Hamdy MA, Azzazy HME-S. Direct detection of hyaluronidase in urine utilizing cationic gold nanoparticles: a possible diagnostic check for bladder most cancers. Biosens Bioelectron. 2014;54:7–14. https://doi.org/10.1016/j.bios.2013.10.024.
Radwan SH, Azzazy HME. Gold nanoparticles for molecular diagnostics. Skilled Rev Mol Diagn. 2009;9:511–24. https://doi.org/10.1586/erm.09.33.
Jain PK, Lee KS, El-Sayed IH, El-Sayed MA. Calculated absorption and scattering properties of gold nanoparticles of various measurement, form, and composition: purposes in organic imaging and biomedicine. J Phys Chem B. 2006;110:7238–48. https://doi.org/10.1021/jp057170o.
Nossier AI, Mohammed OS, Fakhr El-Deen RR, Zaghloul AS, Eissa S. Gelatin-modified gold nanoparticles for direct detection of urinary whole gelatinase exercise: diagnostic worth in bladder most cancers. Talanta. 2016;161:511–9. https://doi.org/10.1016/j.talanta.2016.09.015.
Eissa S, Shawky SM, Matboli M, Mohamed S, Azzazy HME. Direct detection of unamplified hepatoma upregulated protein RNA in urine utilizing gold nanoparticles for bladder most cancers analysis. Clin Biochem. 2014;47:104–10. https://doi.org/10.1016/j.clinbiochem.2013.10.022.
Liu T, Yuan X, Xu D. Most cancers-specific telomerase reverse transcriptase (TERT) promoter mutations: organic and medical implications. Genes (Basel). 2016. https://doi.org/10.3390/genes7070038.
Shay JW, Wright WE. Telomeres and telomerase: three many years of progress. Nat Rev Genet. 2019;20:299–309. https://doi.org/10.1038/s41576-019-0099-1.
Zou L, Li X, Zhang J, Ling L. A extremely delicate catalytic hairpin assembly-based dynamic light-scattering biosensors for telomerase detection in bladder most cancers analysis. Anal Chem. 2020;92:12656–62. https://doi.org/10.1021/acs.analchem.0c02858.
Tan WS, Tan WP, Tan M-Y, Khetrapal P, Dong L, deWinter P, et al. Novel urinary biomarkers for the detection of bladder most cancers: a scientific assessment. Most cancers Deal with Rev. 2018;69:39–52. https://doi.org/10.1016/j.ctrv.2018.05.012.
Pederzoli F, Murati Amador B, Samarska I, Lombardo KA, Kates M, Bivalacqua TJ, et al. Analysis of urothelial carcinoma in situ utilizing blue gentle cystoscopy and the utility of immunohistochemistry in blue light-positive lesions recognized as atypical. Hum Pathol. 2019;90:1–7. https://doi.org/10.1016/j.humpath.2019.04.018.
Jahnson S, Wiklund F, Duchek M, Mestad O, Rintala E, Hellsten S, et al. Outcomes of second-look resection after major resection of T1 tumour of the urinary bladder. Scand J Urol Nephrol. 2005;39:206–10. https://doi.org/10.1080/00365590510007793-1.
Zurkirchen MA, Sulser T, Gaspert A, Hauri D. Second transurethral resection of superficial transitional cell carcinoma of the bladder: a should even for knowledgeable urologists. Urol Int. 2004;72:99–102. https://doi.org/10.1159/000075961.
Chang TC, Marcq G, Kiss B, Trivedi DR, Mach KE, Liao JC. Picture-guided transurethral resection of bladder tumors—present apply and future outlooks. Bladder Most cancers. 2017;3:149–59. https://doi.org/10.3233/BLC-170119.
Kriegmair M, Baumgartner R, Knüchel R, Stepp H, Hofstädter F, Hofstetter A. Detection of early bladder most cancers by 5-aminolevulinic acid induced porphyrin fluorescence. J Urol. 1996;155:105–9 (dialogue 109).
Witjes JA, Douglass J. The function of hexaminolevulinate fluorescence cystoscopy in bladder most cancers. Nat Clin Pract Urol. 2007;4:542–9. https://doi.org/10.1038/ncpuro0917.
Mark JR, Gelpi-Hammerschmidt F, Trabulsi EJ, Gomella LG. Blue gentle cystoscopy for detection and remedy of non-muscle invasive bladder most cancers. Can J Urol. 2012;19:6227–31.
Zang Z, Wu Q, Chiong E. Blue-light cystoscopy and narrow-band imaging in bladder most cancers administration. Formos J Surg. 2019;52:155. https://doi.org/10.4103/fjs.fjs_133_18.
Kausch I, Sommerauer M, Montorsi F, Stenzl A, Jacqmin D, Jichlinski P, et al. Photodynamic analysis in non-muscle-invasive bladder most cancers: a scientific assessment and cumulative evaluation of potential research. Eur Urol. 2010;57:595–606. https://doi.org/10.1016/j.eururo.2009.11.041.
Draga ROP, Bosch JLHR, Grimbergen MCM. Noninvasive transitional cell carcinoma is related to a excessive prevalence of false positives in photodynamic analysis. Eur Urol. 2009;56:1095–6. https://doi.org/10.1016/j.eururo.2009.07.025.
Davis RM, Kiss B, Trivedi DR, Metzner TJ, Liao JC, Gambhir SS. Floor-enhanced raman scattering nanoparticles for multiplexed imaging of bladder most cancers tissue permeability and molecular phenotype. ACS Nano. 2018;12:9669–79. https://doi.org/10.1021/acsnano.8b03217.
Lin T-Y, Li Y, Liu Q, Chen J-L, Zhang H, Lac D, et al. Novel theranostic nanoporphyrins for photodynamic analysis and trimodal remedy for bladder most cancers. Biomaterials. 2016;104:339–51. https://doi.org/10.1016/j.biomaterials.2016.07.026.
Hafeez S, Huddart R. Advances in bladder most cancers imaging. BMC Med. 2013;11:104. https://doi.org/10.1186/1741-7015-11-104.
Verma S, Rajesh A, Prasad SR, Gaitonde Okay, Lall CG, Mouraviev V, et al. Urinary bladder most cancers: function of MR imaging. Radiographics. 2012;32:371–87. https://doi.org/10.1148/rg.322115125.
Bostrom PJ, van Rhijn BWG, Fleshner N, Finelli A, Jewett M, Thoms J, et al. Staging and staging errors in bladder most cancers. Eur Urol Suppl. 2010;9:2–9. https://doi.org/10.1016/j.eursup.2010.01.005.
Key J, Dhawan D, Cooper CL, Knapp DW, Kim Okay, Kwon IC, et al. Multicomponent, peptide-targeted glycol chitosan nanoparticles containing ferrimagnetic iron oxide nanocubes for bladder most cancers multimodal imaging. Int J Nanomedicine. 2016;11:4141–55. https://doi.org/10.2147/IJN.S109494.
Sweeney SK, Luo Y, O’Donnell MA, Assouline JG. Peptide-mediated concentrating on mesoporous silica nanoparticles: a novel software for preventing bladder most cancers. J Biomed Nanotechnol. 2017;13:232–42. https://doi.org/10.1166/jbn.2017.2339.
Deserno WMLLG, Harisinghani MG, Taupitz M, Jager GJ, Witjes JA, Mulders PF, et al. Urinary bladder most cancers: preoperative nodal staging with ferumoxtran-10-enhanced MR imaging. Radiology. 2004;233:449–56. https://doi.org/10.1148/radiol.2332031111.
Birkhäuser FD, Studer UE, Froehlich JM, Triantafyllou M, Bains LJ, Petralia G, et al. Mixed ultrasmall superparamagnetic particles of iron oxide-enhanced and diffusion-weighted magnetic resonance imaging facilitates detection of metastases in normal-sized pelvic lymph nodes of sufferers with bladder and prostate most cancers. Eur Urol. 2013;64:953–60. https://doi.org/10.1016/j.eururo.2013.07.032.
Thoeny HC, Triantafyllou M, Birkhaeuser FD, Froehlich JM, Tshering DW, Binser T, et al. Mixed ultrasmall superparamagnetic particles of iron oxide-enhanced and diffusion-weighted magnetic resonance imaging reliably detect pelvic lymph node metastases in normal-sized nodes of bladder and prostate most cancers sufferers. Eur Urol. 2009;55:761–9. https://doi.org/10.1016/j.eururo.2008.12.034.
Zhu A, Lee D, Shim H. Metabolic positron emission tomography imaging in most cancers detection and remedy response. Semin Oncol. 2011;38:55–69. https://doi.org/10.1053/j.seminoncol.2010.11.012.
Rohren EM, Turkington TG, Coleman RE. Scientific purposes of PET in oncology. Radiology. 2004;231:305–32. https://doi.org/10.1148/radiol.2312021185.
Jana S, Blaufox MD. Nuclear medication research of the prostate, testes, and bladder. Semin Nucl Med. 2006;36:51–72. https://doi.org/10.1053/j.semnuclmed.2005.09.001.
Ahlström H, Malmström PU, Letocha H, Andersson J, Långström B, Nilsson S. Positron emission tomography within the analysis and staging of urinary bladder most cancers. Acta Radiol. 1996;37:180–5. https://doi.org/10.1177/02841851960371P137.
Cui L, Xiong C, Zhou M, Shi S, Chow DS-L, Li C. Integrin αvβ3-targeted [64Cu]CuS nanoparticles for PET/CT imaging and photothermal ablation remedy. Bioconjug Chem. 2018;29:4062–71. https://doi.org/10.1021/acs.bioconjchem.8b00690.
Elgqvist J. Nanoparticles as theranostic automobiles in experimental and medical applications-focus on prostate and breast most cancers. Int J Mol Sci. 2017. https://doi.org/10.3390/ijms18051102.
Zhou T, Dangle D, Li Y, Zhang J, Wu H, Wang H, et al. Position of Gd2O3-doped carbon-11-choline-lenvatinib nanoparticles distinction agent PET/CT within the analysis of sufferers with lung most cancers. Oncol Lett. 2020;19:1117–24. https://doi.org/10.3892/ol.2019.11243.
Gasión JPB, Cruz JFJ. Enhancing efficacy of intravesical chemotherapy. Eur Urol. 2006;50:225–34. https://doi.org/10.1016/j.eururo.2006.05.035.
Decaestecker Okay, Oosterlinck W. Managing the hostile occasions of intravesical bacillus Calmette-Guérin remedy. Res Rep Urol. 2015;7:157–63. https://doi.org/10.2147/RRU.S63448.
Azuma I, Seya T. Growth of immunoadjuvants for immunotherapy of most cancers. Int Immunopharmacol. 2001;1:1249–59. https://doi.org/10.1016/S1567-5769(01)00055-8.
Nakamura T, Fukiage M, Higuchi M, Nakaya A, Yano I, Miyazaki J, et al. Nanoparticulation of BCG-CWS for utility to bladder most cancers remedy. J Management Launch. 2014;176:44–53. https://doi.org/10.1016/j.jconrel.2013.12.027.
Erdoğar N, Iskit AB, Eroğlu H, Sargon MF, Mungan NA, Bilensoy E. Antitumor efficacy of bacillus calmette-guerin loaded cationic nanoparticles for intravesical immunotherapy of bladder tumor induced rat mannequin. J Nanosci Nanotechnol. 2015;15:10156–64. https://doi.org/10.1166/jnn.2015.11690.
Jing X, Yang F, Shao C, Wei Okay, Xie M, Shen H, et al. Position of hypoxia in most cancers remedy by regulating the tumor microenvironment. Mol Most cancers. 2019;18:157. https://doi.org/10.1186/s12943-019-1089-9.
Sharma A, Arambula JF, Koo S, Kumar R, Singh H, Sessler JL, et al. Hypoxia-targeted drug supply. Chem Soc Rev. 2019;48:771–813. https://doi.org/10.1039/c8cs00304a.
Lin W, Liu H, Chen L, Chen J, Zhang D, Cheng Q, et al. Pre-clinical MRI-guided intravesical instillation theranosis of bladder most cancers by tumor-selective oxygen nanogenerator. Nano In the present day. 2021;38: 101124. https://doi.org/10.1016/j.nantod.2021.101124.
Tyagi P, Tyagi S, Kaufman J, Huang L, de Miguel F. Native drug supply to bladder utilizing expertise improvements. Urol Clin North Am. 2006;33(519–30):x. https://doi.org/10.1016/j.ucl.2006.06.012.
Yoon HY, Yang HM, Kim CH, Goo YT, Kang MJ, Lee S, et al. Present standing of the event of intravesical drug supply programs for the remedy of bladder most cancers. Skilled Opin Drug Deliv. 2020;17:1555–72. https://doi.org/10.1080/17425247.2020.1810016.
Chang L-C, Wu S-C, Tsai J-W, Yu T-J, Tsai T-R. Optimization of epirubicin nanoparticles utilizing experimental design for enhanced intravesical drug supply. Int J Pharm. 2009;376:195–203. https://doi.org/10.1016/j.ijpharm.2009.04.045.
Jin X, Zhang P, Luo L, Cheng H, Li Y, Du T, et al. Environment friendly intravesical remedy of bladder most cancers with cationic doxorubicin nanoassemblies. Int J Nanomedicine. 2016;11:4535–44. https://doi.org/10.2147/IJN.S103994.
von der Maase H, Hansen SW, Roberts JT, Dogliotti L, Oliver T, Moore MJ, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in superior or metastatic bladder most cancers: outcomes of a giant, randomized, multinational, multicenter, section III research. J Clin Oncol. 2000;18:3068–77. https://doi.org/10.1200/jco.2000.18.17.3068.
Denis L. Anaphylactic reactions to repeated intravesical instillation with cisplatin. Lancet. 1983;1:1378–9. https://doi.org/10.1016/s0140-6736(83)92153-0.
Kates M, Date A, Yoshida T, Afzal U, Kanvinde P, Babu T, et al. Preclinical analysis of intravesical cisplatin nanoparticles for non-muscle-invasive bladder most cancers. Clin Most cancers Res. 2017;23:6592–601. https://doi.org/10.1158/1078-0432.CCR-17-1082.
Huang C, Neoh KG, Xu L, Kang ET, Chiong E. Polymeric nanoparticles with encapsulated superparamagnetic iron oxide and conjugated cisplatin for potential bladder most cancers remedy. Biomacromol. 2012;13:2513–20. https://doi.org/10.1021/bm300739w.
Males Okay, Liu W, Li L, Duan X, Wang P, Gou M, et al. Delivering instilled hydrophobic drug to the bladder by a cationic nanoparticle and thermo-sensitive hydrogel composite system. Nanoscale. 2012;4:6425–33. https://doi.org/10.1039/c2nr31592k.
Bilensoy E, Sarisozen C, Esendağli G, Doğan AL, Aktaş Y, Sen M, et al. Intravesical cationic nanoparticles of chitosan and polycaprolactone for the supply of Mitomycin C to bladder tumors. Int J Pharm. 2009;371:170–6. https://doi.org/10.1016/j.ijpharm.2008.12.015.
Martin DT, Hoimes CJ, Kaimakliotis HZ, Cheng CJ, Zhang Okay, Liu J, et al. Nanoparticles for urothelium penetration and supply of the histone deacetylase inhibitor belinostat for remedy of bladder most cancers. Nanomedicine. 2013;9:1124–34. https://doi.org/10.1016/j.nano.2013.05.017.
Knemeyer I, Wientjes MG, Au JL. Cremophor reduces paclitaxel penetration into bladder wall throughout intravesical remedy. Most cancers Chemother Pharmacol. 1999;44:241–8. https://doi.org/10.1007/s002800050973.
Lu Z, Yeh T-Okay, Tsai M, Au JL-S, Wientjes MG. Paclitaxel-loaded gelatin nanoparticles for intravesical bladder most cancers remedy. Clin Most cancers Res. 2004;10:7677–84. https://doi.org/10.1158/1078-0432.CCR-04-1443.
Tsallas A, Jackson J, Burt H. The uptake of paclitaxel and docetaxel into ex vivo porcine bladder tissue from polymeric micelle formulations. Most cancers Chemother Pharmacol. 2011;68:431–44. https://doi.org/10.1007/s00280-010-1499-2.
Mugabe C, Hadaschik BA, Kainthan RK, Brooks DE, So AI, Gleave ME, et al. Paclitaxel included in hydrophobically derivatized hyperbranched polyglycerols for intravesical bladder most cancers remedy. BJU Int. 2009;103:978–86. https://doi.org/10.1111/j.1464-410X.2008.08132.x.
McKiernan JM, Barlow LJ, Laudano MA, Mann MJ, Petrylak DP, Benson MC. A section I trial of intravesical nanoparticle albumin-bound paclitaxel within the remedy of bacillus Calmette-Guérin refractory nonmuscle invasive bladder most cancers. J Urol. 2011;186:448–51. https://doi.org/10.1016/j.juro.2011.03.129.
McKiernan JM, Holder DD, Ghandour RA, Barlow LJ, Ahn JJ, Kates M, et al. Section II trial of intravesical nanoparticle albumin certain paclitaxel for the remedy of nonmuscle invasive urothelial carcinoma of the bladder after bacillus Calmette-Guérin remedy failure. J Urol. 2014;192:1633–8. https://doi.org/10.1016/j.juro.2014.06.084.
Robins DJ, Sui W, Matulay JT, Ghandour R, Anderson CB, DeCastro GJ, et al. Lengthy-term survival outcomes with intravesical nanoparticle albumin-bound paclitaxel for recurrent non-muscle-invasive bladder most cancers after earlier bacillus Calmette-Guérin remedy. Urology. 2017;103:149–53. https://doi.org/10.1016/j.urology.2017.01.018.
Chang SS, Bochner BH, Chou R, Dreicer R, Kamat AM, Lerner SP, et al. Remedy of non-metastatic muscle-invasive bladder most cancers: AUA/ASCO/ASTRO/SUO guideline. J Urol. 2017;198:552–9. https://doi.org/10.1016/j.juro.2017.04.086.
Witjes JA, Bruins HM, Cathomas R, Compérat EM, Cowan NC, Gakis G, et al. European affiliation of urology tips on muscle-invasive and metastatic bladder most cancers: abstract of the 2020 tips. Eur Urol. 2021;79:82–104. https://doi.org/10.1016/j.eururo.2020.03.055.
Grossman HB, Natale RB, Tangen CM, Speights VO, Vogelzang NJ, Trump DL, et al. Neoadjuvant chemotherapy plus cystectomy in contrast with cystectomy alone for regionally superior bladder most cancers. N Engl J Med. 2003;349:859–66. https://doi.org/10.1056/NEJMoa022148.
Yin M, Joshi M, Meijer RP, Glantz M, Holder S, Harvey HA, et al. Neoadjuvant chemotherapy for muscle-invasive bladder most cancers: a scientific assessment and two-step meta-analysis. Oncologist. 2016;21:708–15. https://doi.org/10.1634/theoncologist.2015-0440.
Sternberg CN, de Mulder P, Schornagel JH, Theodore C, Fossa SD, van Oosterom AT, et al. Seven 12 months replace of an EORTC section III trial of high-dose depth M-VAC chemotherapy and G-CSF versus basic M-VAC in superior urothelial tract tumours. Eur J Most cancers. 2006;42:50–4. https://doi.org/10.1016/j.ejca.2005.08.032.
Ko Y-J, Canil CM, Mukherjee SD, Winquist E, Elser C, Eisen A, et al. Nanoparticle albumin-bound paclitaxel for second-line remedy of metastatic urothelial carcinoma: a single group, multicentre, section 2 research. Lancet Oncol. 2013;14:769–76. https://doi.org/10.1016/S1470-2045(13)70162-1.
Lin T-Y, Zhang H, Luo J, Li Y, Gao T, Lara PN, et al. Multifunctional concentrating on micelle nanocarriers with each imaging and therapeutic potential for bladder most cancers. Int J Nanomedicine. 2012;7:2793–804. https://doi.org/10.2147/IJN.S27734.
Lin T-Y, Li Y-P, Zhang H, Luo J, Goodwin N, Gao T, et al. Tumor-targeting multifunctional micelles for imaging and chemotherapy of superior bladder most cancers. Nanomedicine (Lond). 2013;8:1239–51. https://doi.org/10.2217/nnm.12.150.
Dhillon SS, Demmy TL, Yendamuri S, Loewen G, Nwogu C, Cooper M, et al. A section I research of sunshine dose for photodynamic remedy utilizing 2-[1-hexyloxyethyl]-2 devinyl pyropheophorbide-a for the remedy of non-small cell carcinoma in situ or non-small cell microinvasive bronchogenic carcinoma: a dose ranging research. J Thorac Oncol. 2016;11:234–41. https://doi.org/10.1016/j.jtho.2015.10.020.
Mao B, Liu C, Zheng W, Li X, Ge R, Shen H, et al. Cyclic cRGDfk peptide and Chlorin e6 functionalized silk fibroin nanoparticles for focused drug supply and photodynamic remedy. Biomaterials. 2018;161:306–20. https://doi.org/10.1016/j.biomaterials.2018.01.045.
Azaïs H, Schmitt C, Tardivel M, Kerdraon O, Stallivieri A, Frochot C, et al. Evaluation of the specificity of a brand new folate-targeted photosensitizer for peritoneal metastasis of epithelial ovarian most cancers to allow intraperitoneal photodynamic remedy. A preclinical research. Photodiagnosis Photodyn Ther. 2016;13:130–8. https://doi.org/10.1016/j.pdpdt.2015.07.005.
Jezek P, Nekvasil M, Skobisová E, Urbánková E, Jirsa M, Zadinová M, et al. Experimental photodynamic remedy with MESO-tetrakisphenylporphyrin (TPP) in liposomes results in disintegration of human amelanotic melanoma implanted to nude mice. Int J Most cancers. 2003;103:693–702. https://doi.org/10.1002/ijc.10857.
Kolarova H, Nevrelova P, Bajgar R, Jirova D, Kejlova Okay, Strnad M. In vitro photodynamic remedy on melanoma cell traces with phthalocyanine. Toxicol In Vitro. 2007;21:249–53. https://doi.org/10.1016/j.tiv.2006.09.020.
Dou QQ, Teng CP, Ye E, Loh XJ. Efficient near-infrared photodynamic remedy assisted by upconversion nanoparticles conjugated with photosensitizers. Int J Nanomedicine. 2015;10:419–32. https://doi.org/10.2147/IJN.S74891.
Guo H, Qian H, Idris NM, Zhang Y. Singlet oxygen-induced apoptosis of most cancers cells utilizing upconversion fluorescent nanoparticles as a provider of photosensitizer. Nanomedicine. 2010;6:486–95. https://doi.org/10.1016/j.nano.2009.11.004.
Yan X, Al-Hayek S, Huang H, Zhu Z, Zhu W, Guo H. Photodynamic impact of 5-aminolevulinic acid-loaded nanoparticles on bladder most cancers cells: a preliminary investigation. Scand J Urol. 2013;47:145–51. https://doi.org/10.3109/00365599.2012.713000.
Ni W, Li M, Cui J, Xing Z, Li Z, Wu X, et al. 808nm gentle triggered black TiO2 nanoparticles for killing of bladder most cancers cells. Mater Sci Eng C Mater Biol Appl. 2017;81:252–60. https://doi.org/10.1016/j.msec.2017.08.020.
Szlachcic A, Pala Okay, Zakrzewska M, Jakimowicz P, Wiedlocha A, Otlewski J. FGF1-gold nanoparticle conjugates concentrating on FGFR effectively lower cell viability upon NIR irradiation. Int J Nanomedicine. 2012;7:5915–27. https://doi.org/10.2147/IJN.S36575.
Alifu N, Zebibula A, Qi J, Zhang H, Solar C, Yu X, et al. Single-molecular near-infrared-II theranostic programs: ultrastable aggregation-induced emission nanoparticles for long-term tracing and environment friendly photothermal remedy. ACS Nano. 2018;12:11282–93. https://doi.org/10.1021/acsnano.8b05937.
Lin T, Zhao X, Zhao S, Yu H, Cao W, Chen W, et al. O2-generating MnO2 nanoparticles for enhanced photodynamic remedy of bladder most cancers by ameliorating hypoxia. Theranostics. 2018;8:990–1004. https://doi.org/10.7150/thno.22465.
Bozzuto G, Molinari A. Liposomes as nanomedical gadgets. Int J Nanomedicine. 2015;10:975–99. https://doi.org/10.2147/IJN.S68861.
Pirollo KF, Rait A, Zhou Q, Zhang X, Zhou J, Kim C-S, et al. Tumor-targeting nanocomplex supply of novel tumor suppressor RB94 chemosensitizes bladder carcinoma cells in vitro and in vivo. Clin Most cancers Res. 2008;14:2190–8. https://doi.org/10.1158/1078-0432.CCR-07-1951.
Martin DT, Steinbach JM, Liu J, Shimizu S, Kaimakliotis HZ, Wheeler MA, et al. Floor-modified nanoparticles improve transurothelial penetration and supply of survivin siRNA in treating bladder most cancers. Mol Most cancers Ther. 2014;13:71–81. https://doi.org/10.1158/1535-7163.MCT-13-0502.
Kang MR, Yang G, Place RF, Charisse Okay, Epstein-Barash H, Manoharan M, et al. Intravesical supply of small activating RNA formulated into lipid nanoparticles inhibits orthotopic bladder tumor progress. Most cancers Res. 2012;72:5069–79. https://doi.org/10.1158/0008-5472.CAN-12-1871.
Miao L, Wang Y, Lin CM, Xiong Y, Chen N, Zhang L, et al. Nanoparticle modulation of the tumor microenvironment enhances therapeutic efficacy of cisplatin. J Management Launch. 2015;217:27–41. https://doi.org/10.1016/j.jconrel.2015.08.027.
Miao L, Liu Q, Lin CM, Luo C, Wang Y, Liu L, et al. Focusing on tumor-associated fibroblasts for therapeutic supply in desmoplastic tumors. Most cancers Res. 2017;77:719–31. https://doi.org/10.1158/0008-5472.CAN-16-0866.
Tao Okay, Liu S, Wang L, Qiu H, Li B, Zhang M, et al. Focused multifunctional nanomaterials with MRI, chemotherapy and photothermal remedy for the analysis and remedy of bladder most cancers. Biomater Sci. 2019;8:342–52. https://doi.org/10.1039/c9bm01377f.
Cho SK, Su L-J, Mao C, Wolenski CD, Flaig TW, Park W. Multifunctional nanoclusters of NaYF4:Yb3+, Er3+ upconversion nanoparticle and gold nanorod for simultaneous imaging and focused chemotherapy of bladder most cancers. Mater Sci Eng C Mater Biol Appl. 2019;97:784–92. https://doi.org/10.1016/j.msec.2018.12.113.
Cheng Z, Li M, Dey R, Chen Y. Nanomaterials for most cancers remedy: present progress and views. J Hematol Oncol. 2021;14:85. https://doi.org/10.1186/s13045-021-01096-0.
Jaishree V, Gupta PD. Nanotechnology: a revolution in most cancers analysis. Indian J Clin Biochem. 2012;27:214–20. https://doi.org/10.1007/s12291-012-0221-z.
Azevedo R, Soares J, Gaiteiro C, Peixoto A, Lima L, Ferreira D, et al. Glycan affinity magnetic nanoplatforms for urinary glycobiomarkers discovery in bladder most cancers. Talanta. 2018;184:347–55. https://doi.org/10.1016/j.talanta.2018.03.028.
Yasui T, Yanagida T, Ito S, Konakade Y, Takeshita D, Naganawa T, et al. Unveiling huge numbers of cancer-related urinary-microRNA candidates through nanowires. Sci Adv. 2017;3: e1701133. https://doi.org/10.1126/sciadv.1701133.
Anselmo AC, Mitragotri S. Nanoparticles within the clinic. Bioeng Transl Med. 2016;1:10–29. https://doi.org/10.1002/btm2.10003.
[ad_2]
